Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.
about
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.
P2860
Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Docetaxel, bevacizumab, and ge ...... s: A single-center experience.
@ast
Docetaxel, bevacizumab, and ge ...... s: A single-center experience.
@en
type
label
Docetaxel, bevacizumab, and ge ...... s: A single-center experience.
@ast
Docetaxel, bevacizumab, and ge ...... s: A single-center experience.
@en
prefLabel
Docetaxel, bevacizumab, and ge ...... s: A single-center experience.
@ast
Docetaxel, bevacizumab, and ge ...... s: A single-center experience.
@en
P2093
P2860
P356
P1476
Docetaxel, bevacizumab, and ge ...... ts: A single-center experience
@en
P2093
Antonio D Logan
Karen B Tamulonis
Karen Fernandez
Kristen L Dalton
Marta Batus
Paul M Kent
Rebecca E Mcfall
P2860
P356
10.1002/PBC.26265
P577
2016-11-05T00:00:00Z